Hong Van Tieu, MD, MS
Head, Laboratory of Infectious Disease Prevention
Associate Member, Lindsley F. Kimball Research Institute
Phone: +1 (212) 570-3081
Established in 1993, the Laboratory of Infectious Disease Prevention is a leader in HIV and infectious disease epidemiology and prevention research. We are part of the largest clinical trials program devoted to the development and testing of preventive HIV vaccines worldwide (www.hvtn.org). We use epidemiology to stay up to date on who is at risk for HIV and other infectious diseases and why. We design and test innovative prevention strategies to increase HIV testing and pre-exposure prophylaxis (PrEP) uptake and reduce risk. We conduct our epidemiology and clinical studies and community engagement through our research site, Project ACHIEVE (www.projectachieve.org).
Our research collaborators include Columbia University, Harlem Prevention Center, and Bronx Prevention Center. Together, we form the NIH-funded Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit.
HIV Vaccine and Monoclonal Antibody Studies
In collaboration with the NIH/NIAID-funded HIV Vaccine Trials Network (HVTN) and with the Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit, our research involves implementation of multiple Phase 1-3 HIV vaccine research trials to test the safety, tolerability, and efficacy of HIV vaccine products and monoclonal antibodies to prevent HIV infection.
HIV Injectable Pre-Exposure Prophylaxis Study
In collaboration with the NIH/NIAID-funded HIV Prevention Trials Network (HPTN), this multi-site, multi-country HPTN 083 study is a Phase 2/3 study comparing injectable cabotegravir to emtricitabine/tenofovir (FTC/TDF) for preventing HIV infection in men who have sex with men and transgender women.
Neighborhoods, Networks, and the HIV Care Continuum
This NIH/NIMH-funded two-phase research study involves a mixed methods approach to ascertain unique, salient neighborhood and network factors that influence HIV care continuum outcomes (retention in care, ART adherence, and viral suppression) among HIV-infected men who have sex with men in New York City using qualitative interviews and spatial analysis and multilevel modeling.
Pre-Exposure Prophylaxis in Women
This NIH R34-funded three-phase project seeks to develop and pilot an intervention to enhance uptake of pre-exposure prophylaxis (PrEP) among women at risk for HIV, and support adherence, and linkage to care in New York City and Philadelphia. Text based messaging will be used to encourage PrEP adherence, and the feasibility and acceptability of the intervention will be tested.
Hepatitis C Infections among Men Who Have Sex with Men
This Merck Investigator Sponsored Program (MISP)-funded research aims to determine the prevalence of recent and chronic hepatitis C (HCV) infections among MSM in NYC, map HCV infections by home, social, and sexual neighborhoods, and determine clusters of genetically linked HCV variants among recently and chronically HCV-infected MSM in NYC using phylogenetic analysis.
Barriers and Facilitators to Blood Donation
This pilot study seeks to identify and describe motivations, barriers, and facilitators to blood donation among Black donors by analyzing YouTube video content and qualitative data analysis.
2UM1A069470 (Hammer/El-Sadr, subcontract to Tieu), 12/1/2013 - 11/30/2020, “Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit”
5UM1AI068614 (Corey, subcontract to Tieu), 12/1/2016 – 11/30/2019, “HVTN 704/HPTN 085 Protocol Funding (PF)” and “HVTN 704/HPTN 085 AMP Study Social and Behavioral Sciences Supplement: Enhancing Enrollment and Retention in US Phase II Clinical Trials– AMP Supplement Project”
2UM1AI068614 (Corey, subcontract to Tieu), 12/1/2016 – 11/30/2019, “Protocol Funds (PF): HIV Vaccine Trials Network (HVTN),” “Scientific Leadership,” “HIV Vaccine Trials Network (HVTN) RAMP Program”
UM1 AI068619 (Cohen, subcontract to Tieu), 1/1/2017 – 12/31/2021, “HIV Prevention Trials Network (HPTN) 083”
1R56MH112401-01A1 (PI Tieu), 9/1/2017 – 8/31/2019, “Influence of Neighborhoods and Networks on the HIV Care Continuum among HIV-infected MSM in NYC”:
R34 MH108437-01A1 (PI Teitelman/Koblin, co-investigator Tieu), 08/05/2016 – 07/31/2019, “Developing a Women-Focused PrEP Intervention for HIV Prevention”
R01DA038108 (PI Frye), 9/2014-8/2019 (NCE), "Testing an Intervention to Increase HIV Self-Testing among Young Black MSM"
R01HD078595 (PI Frye), 8/2013-3/2019, "Using technology to match young Black MSM to HIV testing options"
- Eddie Bravo, AS, Recruitment Specialist
- Tarashon Broomes, DNP, APRN, AGNP-C, Research Clinician
- Nikki Englert, Senior Research Counselor
- Jay Loeffel, MEd, MPA, Senior Administrator
- Angela Lomax, BSN, Research Nurse
- Debbie Lucy, MS, Director of Clinical Studies
- Ashton McGown, BS, Fiscal/Administrative Specialist
- Major Nesby, BA, Recruitment Specialist
- Geneva Ortiz, AA, Clinical Research Specialist
- Kiwan Stewart, BPS, Supervisor Clinical Studies
- DaShawn Usher, BS, Community Engagement and Recruitment manager
- Tasha Vazquez, BS, Administrator
Education and Training
MD, Mount Sinai School of Medicine
MS, Epidemiology, Columbia University Mailman School of Public Health
Internal medicine residency, Department of Medicine, Boston University Medical Center
Infectious diseases fellowship, Division of Infectious Diseases/Department of Medicine, Columbia University Medical Center
Infectious disease epidemiology research fellowship, Center for Infectious Disease Epidemiologic Research, Columbia University Mailman School of Public Health
Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018.
Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Tieu HV, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC2; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network. PLoS Med 2017;14(11):e1002435. doi:10.1371/journal.pmed.1002435.
Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network. DNA priming increases frequency of T-cell responses to a VSV HIV vaccine with specific enhancement of CD8+ T-cell responses by IL-12 pDNA. Clin Vaccine Immunol 2017. pii: CVI.00263-17. doi: 10.1128/CVI.00263-17.
Richardson S, Seekaew P, Koblin B, Vazquez T, Nandi V, Tieu HV. Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. PLoS One 2017;12(7):e0181702. doi: 10.1371/journal.pone.0181702. eCollection 2017.
Markowitz M, Frank I, Grant RM, Mayer KM, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Tieu HV, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart, AR, Smith KY. Spreen W. ECLAIR: a randomised phase IIa safety and pharmacokinetic study of cabotegravir long-1 acting injection 800 mg every 12 weeks in HIV-uninfected men. Lancet Infectious Diseases 2017;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1.
Frye V, Nandi V, Egan JE, Cerda M, Rundle A, Quinn JW, Sheehan D, Ompad DC, Tieu HV, Greene E, Koblin B. Associations Among Neighborhood Characteristics and Sexual Risk Behavior Among Black and White MSM Living in a Major Urban Area. AIDS Behav 2016; 21(3):870-890. doi: 10.1007/s10461-016-1596-2.
Tieu HV, Nandi V, Hoover DR, Lucy D, Stewart K, Frye V, Cerda M, Ompad D, Latkin C, Koblin BA on behalf of the NYC M2M Study Team. Do Sexual Networks of Men Who Have Sex with Men in New York City Differ by Race/Ethnicity? AIDS Patient Care and STDs 2016: 30(1):39-47. doi:10.1089/apc.2015.0237.
Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C; HPTN 061. Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities. PLoS ONE 2015: 10(8):e0134085. doi: 10.1371/journal.pone.0134085.
Tieu HV, Nandi V, Frye V, Stewart K, Oquendo H, Bush B, Cerda M, Hoover DR, Ompad D, Koblin BA. Concurrent Partnerships and HIV Risk among Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2014:41(3):200-8.
Tieu HV, Rolland M, Hammer S, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. JAIDS 2013:63 Suppl 2:S150-4.
Tieu HV, Li X, Donnell D, Vittinghoff E, Buchbinder S, Parente ZG, Koblin BA. Anal Sex Role Segregation and Versatility among Men Who Have Sex with Men: EXPLORE Study. JAIDS 2013;64(1):121-125.
Edwards-Jackson N, Phanuphak N, Tieu HV, Chomchey N, Teeratakulpisarn N, Sathienthammawit W, Pakam C, Pharachetsakul N, Sobieszczyk ME, Phanuphak P, Ananworanich J. HIV Serostatus Disclosure is Not Associated with Safer Sexual Behavior among HIV-positive Men Who Have Sex with Men and Their Partners at Risk for Infection in Bangkok, Thailand. AIDS Research and Therapy 2012;9(1):38.
Tieu HV, Spikes P, Patterson J, Bonner S, Egan JE, Goodman K, Stewart K, Frye V, Xu G, Hoover DR, Koblin BA. Sociodemographic and Risk Behavior Characteristics Associated with Unprotected Sex with Women among Black Men Who Have Sex with Men and Women in New York City. AIDS Care 2012;24(9):1111-9.
Tieu HV, Xu G, Bonner S, Spikes P, Egan JE, Goodman K, Stewart K, Koblin BA. Sexual Partner Characteristics, Serodiscordant/Serostatus Unknown Unprotected Anal Intercourse and Disclosure among HIV-infected and Uninfected Black Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2011;38(6):548-54.
Tieu HV, Murrill C, Xu G, Koblin BA. Sexual Partnering and HIV Risk among Black Men Who Have Sex With Men: New York City. Journal of Urban Health 2010;87:113-21.